DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zemuron (Rocuronium Bromide) - Summary

 
 



ZEMURON SUMMARY

ZEMURON® (rocuronium bromide) Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration.

ZEMURON® (rocuronium bromide) Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration and is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.


See all Zemuron indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zemuron (Rocuronium)

Are the cognitive side effects of anesthesia overlooked?
Source: Pain / Anesthetics News From Medical News Today [2014.08.19]
Although guidelines are commonly in place to minimize pain-related side effects of anesthesia, a new survey finds that less attention is paid to the risk of cognitive side effects.

For pediatric knee surgery, regional anesthesia reduces pain, speeds recovery
Source: Bones / Orthopedics News From Medical News Today [2014.08.14]
A recent study of an ultrasound-guided regional anesthesia technique, called femoral nerve block, shows that it leads to less opioid use and allows the majority of patients to go home within hours of...

Potential new treatment for people with PTSD: Xenon exposure shown to erase traumatic memories
Source: Anxiety / Stress News From Medical News Today [2014.08.29]
McLean Hospital researchers are reporting that xenon gas, used in humans for anesthesia and diagnostic imaging, has the potential to be a treatment for post-traumatic stress disorder (PTSD) and other...

Spotlight on nurse anesthetists in Clinical Scholars Review
Source: Nursing / Midwifery News From Medical News Today [2014.06.02]
As a profession, nurse anesthesia is at a tipping point. While recent federal legislation and changes to the U.S.

more news >>

Published Studies Related to Zemuron (Rocuronium)

Succinylcholine versus rocuronium for rapid sequence intubation in intensive care: a prospective, randomized controlled trial. [2011.08.16]
INTRODUCTION: Succinylcholine and rocuronium are widely used to facilitate rapid sequence induction (RSI) intubation in intensive care. Concerns relate to the side effects of succinylcholine and to slower onset and inferior intubation conditions associated with rocuronium. So far, succinylcholine and rocuronium have not been compared in an adequately powered randomized trial in intensive care. Accordingly, the aim of the present study was to compare the incidence of hypoxemia after rocuronium or succinylcholine in critically ill patients requiring an emergent RSI... CONCLUSIONS: In critically ill patients undergoing emergent RSI, incidence and severity of oxygen desaturations, the quality of intubation conditions, and incidence of failed intubation attempts did not differ between succinylcholine and rocuronium. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00355368.

A comparative study between 1 and 2 effective doses of rocuronium for intraoperative neuromonitoring during thyroid surgery. [2011.04]
BACKGROUND: The goal of this study was to explore an ideal application of rocuronium to enable adequate muscle relaxation for intubation without significantly affecting the evoked potentials measured by intraoperative neuromonitoring during thyroid surgery... CONCLUSION: A total of 1 ED(95) of rocuronium (0.3 mg/kg) is an optimal dose for intraoperative neuromonitoring during thyroid surgery. Positive and high EMG signals were obtained in all patients at an early stage of operation, and satisfactory intubating conditions were achieved in most patients. Copyright (c) 2011 Mosby, Inc. All rights reserved.

A randomized trial to identify optimal precurarizing dose of rocuronium to avoid precurarization-induced neuromuscular block. [2011.04]
PURPOSE: The aim of this study was to examine the safe precurarizing dose of rocuronium required to avoid neuromuscular block after precurarization... CONCLUSION: Rocuronium at 0.06 mg/kg is an overdose for precurarization. The results of the present study demonstrate that a safe and effective precurarizing dose of rocuronium is 0.03 mg/kg.

The effect of low dose rocuronium on intraocular pressure in laryngeal mask airway usage. [2011.02]
CONCLUSION: Although there have been reports that LMA insertion minimally increases IOP, in our study, by using low dose rocuronium and LMA there was a decrease in IOP.

Desaturation following rapid sequence induction using succinylcholine vs. rocuronium in overweight patients. [2011.02]
BACKGROUND: Rapid sequence induction may be associated with hypoxemia. The purpose of this study was to investigate the possible difference in desaturation during rapid sequence induction in overweight patients using either succinylcholine or rocuronium... CONCLUSIONS: Succinylcholine was associated with a significantly more rapid desaturation and longer recovery of oxygen saturation than rocuronium during rapid sequence induction in overweight patients. (c) 2011 The Authors. Journal compilation (c) 2011 The Acta Anaesthesiologica Scandinavica Foundation.

more studies >>

Clinical Trials Related to Zemuron (Rocuronium)

A Study to Determine the Dose Requirements of Rocuronium Bromide (ZemuronŽ) in Pediatric and Adolescent Subjects [Completed]
The primary purpose of this study is to determine the dose requirements of rocuronium bromide when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) and when administered by either continuous infusion or bolus doses for maintenance of muscle relaxation in term neonates (birth to <28 days old), infants and toddlers (28 days to less than or equal to 24 months old), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).

MgSO4 Combined With Rocuronium Priming [Recruiting]
Priming with either rocuronium or MgSO4 is known to accelerate the effect of rocuronium on muscle relaxation. The purpose of this study is to define the effect of MgSO4 on the rocuronium-priming.

The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy [Recruiting]
Eighty subjects will be recruited from those scheduled for surgery requiring general anesthesia at St Vincent's Hospital. Subjects must have American Society of Anesthesiologists (ASA) status of 1 or 2 (be fairly healthy), a BMI between 18-35 (reasonably healthy weight), and be between the ages of 18 and 75. They will not be eligible if they take certain medications or are expected to have a difficult intubation.

Subjects will be randomized (assigned by chance) to one of four rocuronium doses of 0, 0. 2, 0. 4, or 0. 6 mg kg-1. All are acceptable clinical doses for performing a laryngoscopy. In the operating room, routine monitors will be applied, including a Bispectral Index (BIS) sensor and an M-Entropy sensor. Subjects will receive 0. 025 mg kg-1 midazolam (a standard pre-op dose) and will be put to sleep. Once asleep, the subject will receive a rocuronium dose, followed by laryngoscopy three minutes later. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. CVI, entropy, amount of muscle relaxation, and vital signs will be monitored and recorded throughout the procedure.

Subjects will receive propofol and remifentanil infusions during the case. These are commonly used medications for anesthesia. The subjects will also be randomized to two additional groups. One group will receive a remifentanil infusion of 2ng ml-1 and the other group will receive a 8ng ml-1 remifentanil infusion. Both doses are acceptable and often used during standard clinical care. The propofol infusion will be adjusted to keep the BIS number between 45-60. The anesthesiologist will not be able to see the CVI value. The times of certain intraoperative events, such as intubation and incision, will be recorded. All subjects will receive a morphine bolus (0. 10-0. 15 mg/kg) towards the end to reduce post-operative pain, as per standard clinical care. As the subject wakes up, time to eye opening and orientation will be recorded. The subject will rate their pain on a numerical pain scale and the quality of emergence will be assessed.

Upon arrival in the post anesthesia care unit (PACU), subjects will be asked to rate their pain again using the same pain scale. The pain score will be evaluated every 10 minutes for half an hour, then every hour until they are discharged from PACU.

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy [Recruiting]
The Bispectral Index monitor is used in many operating rooms to provide information to the anesthesiologist about a patient's level of consciousness. The Composite Variability Index, or Composite Variability Index (CVI), is a new index that may provide the anesthesiologist with more information about the condition of the patient. The purpose of this study is to determine if a commonly used anesthetic drug (rocuronium) affects the CVI measurement differently with different doses. Rocuronium is a muscle relaxant routinely used during surgery. It is expected that the group given the highest dose of rocuronium will have diminished CVI values.

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia [Completed]

more trials >>


Page last updated: 2014-08-29

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014